Valuation: Verastem, Inc.

Market Cap 680M 589M 556M 505M 946M 65.19B 953M 6.64B 2.56B 33.07B 2.55B 2.5B 105B P/E 2026 *
-4.68x
P/E 2027 * -6.45x
Enterprise Value 722M 626M 590M 536M 1B 69.2B 1.01B 7.05B 2.72B 35.11B 2.71B 2.65B 112B EV / Sales 2026 *
6.2x
EV / Sales 2027 * 3.75x
Free-Float
98.98%
Yield 2026 *
-
Yield 2027 * -
1 day+2.60%
1 week-8.41%
Current month+4.02%
1 month+14.13%
3 months+83.17%
6 months+34.11%
Current year-2.72%
1 week 7.25
Extreme 7.25
8.38
1 month 6.45
Extreme 6.45
8.54
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
10.82
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 A Sell

Chief Executive Officer

-1,302 0.0021%
5/21/26 A Free

Director

108,000 0.1229%
5/21/26 A Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
+2.60%-8.41%-22.74%-22.50% 680M
+5.04%+3.66%+50.62%+103.77% 70.24B
-0.71%-0.49%+35.05%+75.73% 62.63B
-3.18%-0.78%-14.14%+369.82% 27.36B
-0.20%-0.53%+26.26%+11.71% 25.71B
+2.20%-4.72%+2.19%-13.14% 24.83B
-0.76%-2.68%+18.44%-21.03% 19.52B
-7.03%-10.19%+161.91%+303.00% 15.51B
-4.66%-6.07%-9.94%+480.25% 14.66B
+4.96%+4.63%-2.75%+864.40% 14.69B
Average -0.18%-2.48%+24.49%+215.20% 27.58B
Weighted average by Cap. +0.56%-0.82%+31.77%+167.28%

Financials

2026 *2027 *
Net sales 116M 101M 95.22M 86.38M 162M 11.16B 163M 1.14B 438M 5.66B 437M 428M 18B 181M 157M 148M 134M 252M 17.36B 254M 1.77B 682M 8.81B 680M 665M 28B
Net income -166M -144M -136M -123M -231M -15.9B -233M -1.62B -624M -8.07B -623M -609M -25.64B -157M -136M -128M -117M -219M -15.05B -220M -1.53B -591M -7.64B -590M -577M -24.28B
Net Debt 41.9M 36.31M 34.26M 31.08M 58.31M 4.02B 58.73M 409M 158M 2.04B 157M 154M 6.48B -
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
14/09/26 $7.510 +2.60% 1,514,530
11/09/26 $7.320 -3.94% 1,913,863
10/09/26 $7.620 -4.03% 2,670,005
09/09/26 $7.940 -1.73% 2,400,611
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
7.510USD
Average target price
15.00USD
Spread / Average Target
+99.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!